Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to -$156.2 million.

  • Takeda Pharmaceutical's Gains from Investment Securities rose 2407.19% to -$156.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 billion, marking a year-over-year decrease of 441.99%. This contributed to the annual value of -$1.1 billion for FY2025, which is 2656.92% up from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Gains from Investment Securities of -$156.2 million as of Q4 2025, which was up 2407.19% from -$374.9 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Gains from Investment Securities ranged from a high of -$156.2 million in Q4 2025 and a low of -$655.2 million during Q3 2022
  • Moreover, its 5-year median value for Gains from Investment Securities was -$334.7 million (2023), whereas its average is -$338.8 million.
  • Within the past 5 years, the most significant YoY rise in Takeda Pharmaceutical's Gains from Investment Securities was 6303.64% (2021), while the steepest drop was 15819.33% (2021).
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Gains from Investment Securities stood at -$250.9 million in 2021, then crashed by 63.45% to -$410.1 million in 2022, then grew by 17.08% to -$340.0 million in 2023, then surged by 39.51% to -$205.7 million in 2024, then grew by 24.07% to -$156.2 million in 2025.
  • Its Gains from Investment Securities stands at -$156.2 million for Q4 2025, versus -$374.9 million for Q3 2025 and -$253.3 million for Q2 2025.